Navigation Links
Cempra Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
Date:11/25/2009

CHAPEL HILL, N.C., Nov. 25 /PRNewswire/ -- Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, president and chief executive officer, will present at the Piper Jaffray 21st Annual Health Care Conference at 8:50 a.m. EST, December 1, 2009, at The New York Palace Hotel in New York City. Dr. Fernandes will provide an overview of the company's two leading antibiotic clinical programs for the treatment of drug-resistant pathogens including MRSA.

About Cempra Pharmaceuticals

Founded in 2006, Cempra Pharmaceuticals is a privately-held, clinical-stage biotechnology company focused on developing antibacterials to address critical medical needs. Two lead products, both in late-stage clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra is well-funded and is committed to developing commercially viable products through consideration of pricing and reimbursement issues throughout its products' lifecycles. The company is also utilizing its proprietary chemistry technology to develop macrolides without antibacterial activity for non-antibiotic uses in motilin receptor activity, anti-inflammatory activity and GnRH receptor antagonism. Additional information about Cempra can be found at www.cempra.com.


Media Contacts:
Robert E. Flamm, Ph.D.
Russo Partners, LLC
+1-212-845-4226
Robert.flamm@russopartnersllc.com

Tony Russo, Ph.D.
Russo Partners, LLC
+1-212-845-4251
Tony.russo@russopartnersllc.com

SOURCE Cempra Pharmaceuticals Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Data Presented on Cempra Pharmaceuticals CEM-101 at the Infectious Diseases Society of America Annual Meeting Reinforces Potency and Coverage Against Multidrug-Resistant S. Pneumoniae Isolates
2. Presentations of Cempra Pharmaceuticals CEM-102 (fusidic acid) at the Infectious Diseases Society of America Annual Meeting Highlight Properties That Make It an Excellent Anti-MRSA Candidate
3. Cempra Pharmaceuticals To Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17th
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , March 28, 2017  Rosen Law Firm, a ... a class action lawsuit on behalf of purchasers of ... ) pursuant and/or traceable to Kitov,s initial public offering ... on the open market from November 20, 2015 through ... The lawsuit seeks to recover damages for Kitov investors ...
(Date:3/28/2017)... , March 29, 2017 ... Siteless CRO platform, announced today study results ... Managed Care Pharmacy, #AMCP2017, Managed Care and Specialty Pharmacy ... . Data in both posters demonstrated that pharmacist-led ... and protocol adherence. These factors are crucial to generating ...
(Date:3/28/2017)... , March 28, 2017 Emosis SAS, ... new business entity, Emosis Ltd, headquartered in Tel Aviv ... novel assays complementing the mother company existing technology platform and test ... sales development of Emosis kits. ... This strategic move starts building Emosis international footprint. Emosis ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... Award-winning medical group Allied Anesthesia ... new board chair for Orange County health care system CalOptima Friday. CalOptima announced ... former chair Mark Refowitz’s term, which runs through June 30 of this year, ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... of corrosive ions found in power plant water and steam. , Chlorides and ... turbines and boilers, leading to extensive maintenance and unplanned shutdowns. Monitoring these ions ...
(Date:3/28/2017)... ... 28, 2017 , ... A minimally invasive porcelain veneer is ... National Association of Dental Laboratories (NADL) is informing dentists about the benefits of ... utilizing dental laboratories and technicians that create these veneers. , According to ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... Conference in Atlantic City March 13-16, was a busy spot this year. Liz ... staff discussed strategies for preventing outbreaks among camp communities during the upcoming 2017 ...
(Date:3/28/2017)... ... ... you to all who attended Capio Partners Winter 2017 Healthcare Leadership Symposium in beautiful ... offered an opportunity to collaborate and network with healthcare colleagues across the United States. ... for a lively discussion on trends and issues that healthcare leaders will face in ...
Breaking Medicine News(10 mins):